TRVI Trevi Therapeutics

Trevi Therapeutics Announces the Hiring of Key Talent

Trevi Therapeutics Announces the Hiring of Key Talent
EN
13/10/2020

Underlying

TRVITrevi Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trevi Therapeutics

 PRESS RELEASE
Free
TRVI Trevi Therapeut...

Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financia...

Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026 Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conf...

20h / 6m 1 EN
 PRESS RELEASE
Free
TRVI Trevi Therapeut...

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with...

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of 2026, with the second pivotal trial expected to initiate in the second half of 2026 NEW HAVEN, Conn., March 09, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the...

March 9, 2026 1 EN
 PRESS RELEASE
Free
TRVI Trevi Therapeut...

Trevi Therapeutics to Participate in Upcoming March Conferences

Trevi Therapeutics to Participate in Upcoming March Conferences NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in March. Leerink Partners 2026 Global Healthcare ConferenceMarch 8 – 11, 2026, Miam...

March 2, 2026 1 EN
 PRESS RELEASE
Free
TRVI Trevi Therapeut...

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healt...

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference Fireside chat with management on February 25, 2026, at 9:20 a.m. ET NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Off...

February 17, 2026 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTWO Take-Two Intera...
SXT Sensient Techno... ... (+39)

InsiderInsights Weekly Tables: April 16, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SXT SENSIENT TECHNOLOGIES CORPORATION
PRTY PARTY CITY HOLDCO INC.
HMTV HEMISPHERE MEDIA GROUP
QRHC QUEST RESOURCE HOLDING
MLI MUELLER INDUSTRIES INC.
PMD PSYCHEMEDICS CORP.
OCX ONCOCYTE
CDZI CADIZ INC.
MRSN MERSANA THERAPEUTICS
CNNE CANNAE HOLDINGS
QNTO QUAINT OAK BANCORP INC.
MMD MAINSTAY DEFINEDTERM MUNICIPAL HIGH INCOME FUND
STIM STIMSONITE CORP
TRVI TREVI THERAPEUTICS
PNTG PENNANT GROUP
PINE ALPINE INCOME PROPERTY TRUST
BDTX BLACK DIAMOND THERAPEUTICS
LYRA INC.
TARA LYRA THERAPEUTICS
IHRT INC.
CCCC PROTEON THERAPEUTICS INC
GRPN IHEARTMEDIA INC. CLASS A
BDSX C4 THERAPEUTICS
JAKK GROUPON INC.
INDT BIODESIX
CRCT JAKKS PACIFIC INC.
AEI INDUS REALTY TRUST INC
GRPH CRICUT
ATAI INC.
FORA ALSET EHOME INTERNATIONAL INC
NYC GRAPHITE BIO
YOU INC.
MYPS ATAI LIFE SCIENCES BV
ABIO FORIAN INC
NEW YORK CITY REIT INC
CLEAR SECURE INC
PLAYSTUDIOS INC
ARCA BIOPHARMA INC
04/16/22 April 16, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch